As in breast cancer, a subset of patients who harbor HER2 amplification in gastric cancer (defined by IHC 3+ or positive FISH) are candidates for HER2-targeted therapy, based on a demonstrated benefit in the ToGA (Trastuzumab for Gastric Cancer) trial. This evidence concerns the gene ERBB2 and breast carcinoma.